Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
Sanchorawala
Vaishali
V
Finn
Kathleen T
KT
Fennessey
Salli
S
Shelton
Anthony
A
Doros
Gheorghe
G
Zeldis
Jerome B
JB
Seldin
David C
DC
D000686:Amyloidosis / Q000097:blood / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood; D000077269:Lenalidomide; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D005938:Glucocorticoids; D007147:Immunoglobulin Light Chains; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide